STOCKS TELEGRAPH

Tag: AGLE

  • Aeglea BioTherapeutics Inc. (AGLE) Surges After Hours on Additional Data for Rare Disorder Presentation

    On April 11, Aeglea BioTherapeutics Inc. (AGLE) stock rallied by nearly 28% in the after-hours trading at a heavy shares traffic of 1.28 million. Thus, the stock surged up to $3.11 a share in the session after it closed the prior session at $2.43 with a decline of 6.54%.

    The reason for the after-hours rally was the additional data presentation from its PEACE Phase 3 study at the SIMD Annual Meeting.

    Source: Northeastern University

    AGLE’s SIMD Presentation

    On Monday, the company shared additional data on pegzilarginase for treating Arginase 1 Deficiency (ARG1-D) presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting. Starting on April 10, the meeting will conclude on April 13, 2022.

    ARG1-D is a rare progressive disease with high levels of arginine while pegzilarginase has so far shown to normalize elevated levels of the amino acid.

    The company’s PEACE Phase 3 study was designed to evaluate the effects of treatment of ARG1-D patients with pegzilarginase, aged two and older. In addition to the previously announced primary endpoint achievement, the presentation at SIMD also included data on patient-level outcomes and additional secondary endpoints.

    According to the president and CEO of AGLE, the new data combined with the old proves the potential of pegzilarginase in changing the lives of ARG1-D patients.

    Global Biotechnology Market

    The global biotechnology market has undergone transformational changes in recent years. The development and innovations associated with molecular biology have ushered new scientific disciplines in the field. Moreover, the global market is expected to grow at a CAGR of over 9.4% between 2021 and 2027.

    AGLE Outlook & Price Revisions

    In recent weeks, AGLE has seen multiple upward revisions in its earnings for the ongoing quarter. Investment analysts at Piper Sandler increased their Q1 2020 earnings estimates from ($0.34) a share to ($0.31).

    Furthermore, Wall Street brokerages are expecting the company to post sales of $1,45 million for this quarter. The full-year sales are expected to be in the range of $5.0 to $6.0 million. With huge growth anticipated in the coming years, the next year’s sales expectations lie at $17.14 million.

    Conclusion

    On Monday, the company posted new data from its ARG1-D study which proved the potential of its candidate in the treatment of rare diseases. Consequently, the stock became bullish and rallies in the after-hours session.

  • Aeglea BioTherapeutics, Inc. (AGLE) Stock Dipping in Early Trading, Here’s the Reason.

    Aeglea BioTherapeutics, Inc. (AGLE) is a clinical-stage biopharmaceutical company engaged in developing human enzyme therapeutics to treat rare metabolic disease patients. One of the lead potential candidates of the company is Pegzilarginase has received RDD and Breakthrough Therapy designations from FDA. AGLE-177 is in Phase 1/2 clinical trials for treating Homocystinuria.

    The price of AGLE stock during the early trading on February 10, 2022, was last checked to be $3.5 with a decline of 6.48%.

    AGLE: Events and Happenings

    On February 9, 2022, AGLE proposed an underwritten public offering to sell its common stock shares and pre-funded warrants for the acquisition of its common stock shares. The company intends to utilize the gross proceeds from the offering to fund its ongoing research projects for the lead candidate pipeline.

    On January 25, 2022, AGLE updated about hosting a Key Opinion Leader and Patient Caregiver Webinar on February 3, 2022. On January 5, 2022, AGLE informed about the participation of its Executive management at the following investor conferences.

    • 40th Annual J.P. Morgan Health Care Conference on January 10-13, and
    • Virtual H.C. Wainwright Bioconnect Conference on January 10-13, 2022.

    On December 6, 2021, the company announced its Phase 3 clinical studies of PEACE, which met the primary endpoint. The company reported a statistically significant decrease from baseline in plasma arginine post-24 weeks of treatment.

    AGLE: Key Financials

    On November 4, 2021, AGLE released its financial results for the third quarter ended September 30, 2021. The main highlights are as follows.

    EPS

    Basic and diluted net loss per share in Q3 2021 totaled $20.3 or $0.31 million compared to $18.0 million or $0.29 in the same quarter of 2020. The company missed the estimated EPS by $0.02 per share.

    Revenue

    Revenue in Q3 2021 was recorded to be $1.39 million compared to nil revenue in the same period of 2020. The company missed the estimated revenue target by $1.29 million.

    Conclusion

    AGLE stock down-performed in the last six months period due to economic restrictions as a result of the pandemic. The company’s stock dipped by 43% in the period. The current early trading stock decline is the result of the company’s announcement of the proposed public offering. The analysts estimate the revenue for the upcoming quarter to be $1.76 million and EPS to be $-$0.31.